Loading organizations...
§ Venture Capital · Brussels, Belgium
European venture capital firm investing in early-stage life sciences and biotechnology companies, building new therapeutics ventures.
Bioqube Ventures is a specialist life sciences venture capital firm based in Brussels, Belgium, that invests in early-stage biotechnology and therapeutics companies. The firm employs a dual strategy by operating as both a traditional equity investor and a venture creator that builds new drug discovery enterprises around emerging scientific research. Operating with a team of 10 professionals, the firm manages the €110 million Bioqube Factory Fund I and maintains a portfolio of over a dozen life sciences companies across Europe and the United States. Bioqube Ventures partners with corporate investors like Genmab and backs notable portfolio companies including Agomab Therapeutics, Aelin Therapeutics, and Navigo Proteins. Agomab Therapeutics recently secured a $100 million Series C funding round to advance its clinical pipeline. Bioqube Ventures was founded in 2016 by Debora Dumont and Nico Vandervelpen.
Key people at Bioqube Ventures.
Bioqube Ventures has 14 tracked investments across 10 companies. The latest tracked deal is $8.6M Series B Extension in Primmune Therapeutics in January 2026.
Key people at Bioqube Ventures.
Bioqube Ventures is a global life sciences investment firm focused on backing bold scientific innovations to develop transformative medicines. Their mission centers on turning early-stage scientific discoveries into first- or best-in-class therapeutics that address significant unmet medical needs. They adopt a stage-agnostic investment philosophy, supporting companies from inception through early clinical milestones, thereby building balanced portfolios that span the full early development spectrum. Key sectors include biopharma and innovative therapeutic technologies. Bioqube Ventures impacts the startup ecosystem by providing not only capital but also specialized infrastructure and expertise, accelerating business growth and reducing costs for early-stage healthcare companies[1][2][3].
Founded in 2015 and headquartered in Belgium with offices in the United States, Bioqube Ventures was established by managing partners including Debora Dumont and Nico Vandervelpen. The firm evolved with a clear focus on life sciences, leveraging deep venture creation experience to translate and de-risk scientific innovation. Their partnership with Johnson & Johnson Innovation (JLINX) exemplifies their multifaceted approach to enable early-stage healthcare companies to reach their potential efficiently and cost-effectively. Over time, Bioqube has expanded its global footprint while maintaining a strong European base, emphasizing early-stage investments in therapeutic assets and technologies[5][2][3].
Bioqube Ventures rides the trend of increasing demand for innovative biopharma solutions addressing unmet medical needs, a sector driven by rapid scientific advances and growing healthcare challenges. The timing is favorable due to heightened global focus on healthcare innovation and the need for efficient translation of lab discoveries into clinical applications. Market forces such as rising investment in life sciences, regulatory support for breakthrough therapies, and strategic collaborations enhance their ability to influence the ecosystem. By bridging capital, expertise, and infrastructure, Bioqube accelerates the development pipeline, contributing to a more dynamic and productive life sciences startup environment[1][2][3].
Looking ahead, Bioqube Ventures is poised to deepen its impact by expanding its portfolio of early-stage therapeutic innovations and leveraging its partnership ecosystem to further de-risk investments. Trends such as personalized medicine, advanced biologics, and digital health integration will likely shape their investment focus. Their influence may grow as they continue to enable startups to navigate complex development stages efficiently, potentially becoming a key catalyst in bringing next-generation medicines to market. This forward momentum ties back to their core mission of backing bold science and building enduring companies that transform healthcare[1][3][2].
